Who
Matthew T. David
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Actinium Pharmaceuticals, Inc. (Delaware); Chief Financial Officer, CorMedix.
In numbers
- Trades disclosed
- 18
- Buys
- 4
- Sells
- 0
- Bought
- $19K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 May 2020
- Last trade
- 14 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 16 Oct 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 14 Oct 2026filed 16 Oct 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $73K6,515 at $11.19 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $71K8,648 at $8.22 | filing |
| 12 Jan 2024filed 17 Jan 2024 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 12 Jan 2024filed 17 Jan 2024 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jan 2024filed 17 Jan 2024 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Code F | $18K5,216 at $3.47 | filing |
| 14 Jan 2023filed 18 Jan 2023 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 18 Feb 2022filed 23 Feb 2022 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | — | filing |
| 6 Dec 2021filed 7 Dec 2021 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $4,5001,000 at $4.50 | filing |
| 6 Dec 2021filed 7 Dec 2021 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $4,5001,000 at $4.50 | filing |
| 17 Nov 2021filed 19 Nov 2021 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $5,0701,000 at $5.07 | filing |
| 1 Nov 2021filed 10 Nov 2021 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 11 Jan 2021filed 13 Jan 2021 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 3 Sep 2020filed 8 Sep 2020 | CRMD CorMedixPharmaceuticals | SEC FORM 4 Bought | $4,6811,150 at $4.07 | filing |
| 11 May 2020filed 13 May 2020 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $704K125,000 at $5.63 | filing |
| 11 May 2020filed 13 May 2020 | CRMD CorMedixoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $510K125,000 at $4.08 | filing |
News
Head-To-Head Survey: Inhibikase Therapeutics (NASDAQ:IKT) versus CorMedix (NASDAQ:CRMD)CRMD · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name Matthew T. David; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.